The ALS Association is committed to making ALS livable for everyone, everywhere, and it will take all of us, working together, to urgently propel research to find new treatments and a cure.
This month, learn more about the latest news and updates on the FDA’s review of tofersen, the status of NurOwn and numerous ALS clinical trials.
The FDA Peripheral and Central Nervous System Drugs Advisory Committee voted 9-0 that a reduction in plasma neurofilament light (NfL) concentration is “reasonably likely” to predict clinical benefit of tofersen for treatment of people with SOD1-ALS.
Dr. Neil Thakur, Dr. Tim Miller and Richard Brennan discuss the FDA's consideration of tofersen, a promising gene therapy for people with ALS who have the SOD1 gene mutation, up for accelerated approval from the FDA in April.
BrainStorm Cell Therapeutics requested that the Center for Biologics Evaluation and Research utilize the FDA's File Over Protest procedure and grant an Advisory Committee meeting to discuss NurOwn. FDA has granted the meeting, but a date for the meeting has not yet been released.
The Sean M. Healey & AMG Center for ALS at Massachusetts General Hospital and the Northeast ALS (NEALS) Consortium announced topline results from Regimen D of the HEALEY ALS Platform Trial, which is evaluating pridopidine versus placebo in adults with ALS.
The ALS Association has awarded $1.6 million to fund four promising preclinical research projects through its Lawrence and Isabel Barnett Drug Development Program.
The 2023 MDA Clinical & Scientific Conference took place in Dallas earlier this month and included a track specifically about ALS. Learn more about the latest information shared.
Clinical trials are the most reliable – and ultimately the fastest – way to translate promising laboratory science into new and better ways to treat and care for people living with ALS.
ALS Focus allows people living with ALS, and current and former caregivers the ability to participate in research outside of clinical trials and is available to all at any stage of the disease. Your opinions matter to help strengthen care, accelerate therapy development, improve clinical trials, influence insurance coverage decisions, and more.
Register to participate in future surveys HERE, and let your voice be heard.
Clinical research is the only way that promising laboratory science can be translated into treatments and cures for ALS and other neurological diseases. People with ALS, along with family members and caregivers, are essential partners in this research. For the most accurate and up-to-date information on both federally and privately funded clinical studies focusing on ALS and other similar motor neuron diseases, visit our website.
The National ALS Registry may be the single largest ALS research project ever created and is designed to identify ALS cases from throughout the entire United States. Every person living with ALS in the U.S. can take part, and there is no fee to participate.
The ALS Association partners with the Northeast ALS Consortium (NEALS) to provide educational webinars for people with ALS, caregivers, and the broader ALS community. Topics include updates on clinical trials, best practices for clinical care, and current research efforts in ALS causes and treatments.
For more detail about current ALS research, the projects we fund, and the numerous focus areas we support, visit als.org/research.
Stay up to date with the latest ALS care news by signing up for our quarterly e-newsletter, Care Matters.
We welcome all feedback, comments and questions you may have on anything about the information provided, suggestions of topics you would like to see in future newsletters or thoughts to help us improve. Please email us at communication@als.org.